Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

STRATEC Aktie 29256738 / DE000STRA555

30.10.2025 15:25:33

EQS-Adhoc: STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025

EQS-Ad-hoc: STRATEC SE / Key word(s): Preliminary Results/Change in Forecast
STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025

30-Oct-2025 / 15:25 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025

Birkenfeld, October 30, 2025

STRATEC SE, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, SDAX), expects to witness temporary interruptions to the supply of input materials for some of its system lines in the fourth quarter of 2025. In particular, in connection with trade policy tensions a supply chain interruption has arisen in recent weeks for a specific type of magnet with impurities relating to export-restricted rare earths (0.1% share of affected production batch). Against this backdrop, delivery backlogs already arose for system deliveries in the third quarter of 2025. Following close communication with its suppliers, STRATEC now no longer expects to receive sufficient quantities of input materials to make up for these delivery backlogs or for the production volumes originally planned for the fourth quarter of 2025. Furthermore, global tariff conflicts are leading to greater fluctuations in customers’ order behavior and to associated inventory optimization measures. These particularly affect the Service Parts and Consumables business.

In view of these factors, the Board of Management has decided to adjust its sales guidance for the 2025 financial year. STRATEC now expects its consolidated sales at constant currency to approximately match the previous year’s figure (previously: “consolidated sales at constant currency to show growth in a low to medium single-digit percentage range”). Despite the lower sales base hereby forecast and negative currency items, STRATEC nevertheless expects to achieve the lower end of the forecast corridor of around 10.0% to 12.0% for its adjusted EBIT margin. This expected intra-year rise in profitability in the fourth quarter of 2025 is attributable to benefits of scale, efficiency measures, and higher earnings contributions from the realization of high-margin development sales.

Based on preliminary figures and despite the delivery backlogs that have already arisen, in the first nine months of 2025 STRATEC was able to increase its consolidated sales at constant currency year-on-year by 2.5% to € 175.6 million (9M/2024: € 173.0 million). The adjusted EBIT margin for the first nine months is expected to amount to 7.3% (9M/2024: 8.8%).

STRATEC will publish its definitive results and its Quarterly Statement for the first nine months of 2025 as planned on November 7, 2025.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com



End of Inside Information

30-Oct-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2221306

 
End of Announcement EQS News Service

2221306  30-Oct-2025 CET/CEST

Analysen zu STRATEC SE

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
23.10.25 STRATEC Hold Deutsche Bank AG
16.09.25 STRATEC Halten DZ BANK
10.09.25 STRATEC Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
22.08.25 STRATEC Hold Hauck Aufhäuser Lampe Privatbank AG
22.08.25 STRATEC Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall

Im BX Morning Call spricht die Schweizer Unternehmer-Ikone Etienne Jornod (OM Pharma) mit François Bloch und Olivia Hähnel (BX Swiss) über Führung, Wachstum, Kooperationen, seine Zeit bei der NZZ und darüber, warum Zuhören der wichtigste Leadership-Skill ist.

Die perfekte Folge für alle, die sich für Pharmastrategien, Galenica/Vifor und Unternehmertum interessieren.

🎯 Themen im Interview mit Etienne Jornod (OM Pharma)

– Antrieb und Führungsphilosophie eines Unternehmers
– Erfolgsweg von Galenica – Lehren aus Jahrzehnten Führung
– Frauenquote, Teamkultur und Leadership bei OM Pharma
– Internationale Expansion: China, USA und neue Märkte
– Forschung, Druck und Verantwortung in der Pharmaindustrie
– Inspiration, Balance und persönliche Haltung zum Erfolg
– Zukunftsvisionen: Schweiz, Unternehmertum und Investments

👉🏽 https://bxplus.ch/bx-musterportfolio/

Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’821.95 19.72 S2S3YU
Short 13’093.54 13.71 UEBSLU
Short 13’578.71 8.95 UIDBSU
SMI-Kurs: 12’301.21 30.10.2025 17:30:00
Long 11’737.17 18.56 SHFB5U
Long 11’508.22 13.79 BBWS3U
Long 11’009.08 8.95 BSXSZU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

STRATEC SE 21.02 -8.63% STRATEC SE